Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study

S Blach, NA Terrault, F Tacke, I Gamkrelidze… - The Lancet …, 2022 - thelancet.com
Background Since the release of the first global hepatitis elimination targets in 2016, and
until the COVID-19 pandemic started in early 2020, many countries and territories were …

Liver fibrosis: mechanistic concepts and therapeutic perspectives

N Roehlen, E Crouchet, TF Baumert - Cells, 2020 - mdpi.com
Liver fibrosis due to viral or metabolic chronic liver diseases is a major challenge of global
health. Correlating with liver disease progression, fibrosis is a key factor for liver disease …

Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

S Blach, S Zeuzem, M Manns, I Altraif… - The lancet …, 2017 - thelancet.com
Summary Background The 69th World Health Assembly approved the Global Health Sector
Strategy to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality …

[HTML][HTML] Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes

A Petruzziello, S Marigliano, G Loquercio… - World journal of …, 2016 - ncbi.nlm.nih.gov
METHODS We conducted a systematic study which represents one of the most
comprehensive effort to quantify global HCV epidemiology, using the best available …

[HTML][HTML] Global epidemiology and genotype distribution of the hepatitis C virus infection

E Gower, C Estes, S Blach, K Razavi-Shearer… - Journal of …, 2014 - Elsevier
The treatment of chronic hepatitis C virus (HCV) infection has the potential to change
significantly over the next few years as therapeutic regimens are rapidly evolving. However …

[PDF][PDF] Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence

F Poordad, ER Schiff, JM Vierling, C Landis… - …, 2016 - Wiley Online Library
Chronic hepatitis C virus (HCV) infection with advanced cirrhosis or post‐liver
transplantation recurrence represents a high unmet medical need with no approved …

Epidemiology and natural history of HCV infection

B Hajarizadeh, J Grebely, GJ Dore - Nature reviews Gastroenterology & …, 2013 - nature.com
Abstract Worldwide, an estimated 130–170 million people have HCV infection. HCV
prevalence is highest in Egypt at> 10% of the general population and China has the most …

Health in the sustainable development goals: ready for a paradigm shift?

K Buse, S Hawkes - Globalization and health, 2015 - Springer
Abstract The Millennium Development Goals (MDGs) galvanized attention, resources and
accountability on a small number of health concerns of low-and middle-income countries …

[PDF][PDF] Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY‐3+)

V Leroy, P Angus, JP Bronowicki, GJ Dore… - …, 2016 - Wiley Online Library
Patients with hepatitis C virus (HCV) genotype 3 infection, especially those with advanced
liver disease, are a challenging population in urgent need of optimally effective therapies …

[HTML][HTML] Innate and adaptive immune responses in HCV infections

MH Heim, R Thimme - Journal of hepatology, 2014 - Elsevier
Hepatitis C virus has been identified a quarter of a decade ago as a leading cause of
chronic viral hepatitis that can lead to cirrhosis and hepatocellular carcinoma. Only a …